[Merck agrees to buy Prometheus for $200 a share] Merck Pharmaceuticals said one of its divisions agreed to buy biotech company Prometheus for $200 a share. The overall equity valuation of the deal is about $10.8 billion and is expected to close in the third quarter of 2023. (Bloomberg)